KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Inovio Pharmaceuticals (INO) Leases (2019 - 2025)

Inovio Pharmaceuticals' Leases history spans 7 years, with the latest figure at $7.0 million for Q3 2025.

  • For Q3 2025, Leases fell 17.89% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $7.0 million, down 17.89%, while the annual FY2024 figure was $8.1 million, 14.52% down from the prior year.
  • Leases for Q3 2025 was $7.0 million at Inovio Pharmaceuticals, down from $7.4 million in the prior quarter.
  • Across five years, Leases topped out at $12.5 million in Q1 2021 and bottomed at $7.0 million in Q3 2025.
  • The 5-year median for Leases is $9.5 million (2023), against an average of $9.8 million.
  • The largest annual shift saw Leases dropped 6.86% in 2024 before it dropped 17.89% in 2025.
  • A 5-year view of Leases shows it stood at $11.6 million in 2021, then dropped by 11.61% to $10.2 million in 2022, then fell by 7.2% to $9.5 million in 2023, then decreased by 14.52% to $8.1 million in 2024, then dropped by 14.26% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Leases are $7.0 million (Q3 2025), $7.4 million (Q2 2025), and $7.7 million (Q1 2025).